December 23, 2015

Evolva achieves stevia milestone

Evolva (SIX: EVE) announces that it has achieved another technical milestone in its partnership with Cargill, Inc. to commercialise EverSweet™, the next-generation, zero-calorie stevia sweetener. Reaching this milestone triggers the payment of USD 0.5 million by Cargill to Evolva.PDF Download - English VersionPDF Download - German Version

December 07, 2015

Evolva launches valencene

Evolva (SIX: EVE) announces the launch of valencene, a highly prized orange flavour and fragrance (F&F) ingredient. As an alternative to extracting it from the skin of oranges, Evolva’s process allows valencene to be made in large amounts in a highly reproducible, contaminant free, sustainable and affordable manner. Evolva has developed a cost efficient manufacturing process at large production scale for valencene and we will start shipping initial commercial samples to prospective clients in January.PDF Download - English VersionPDF Download - German Version

December 01, 2015

Novimmune’s Experimental Drug Selected for Oral Presentation at 2015 Annual Meeting of the American Society of Hematology (ASH)

Late-Breaking Abstract on NI-0501 for Treatment of Hemophagocytic Lymphohistiocytosis (HLH) One of Only Eight Accepted

Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory and rare diseases, immune-related disorders and cancer, today announced that the abstract on Hemophagocytic Lymphohistiocytosis (HLH) will be presented in the Late-Breaking Abstracts oral session at the 2015 Annual Meeting of the American Society of Hematology in Orlando, Florida on Tuesday, December 8.PDF Download

October 13, 2015

PREQIN confirms top performance of ARAVIS’ energy fund

Over the past six years, Aravis Energy I LP has successfully invested in renewable energy assets across Europe. Following the last two exits earlier this year, the fund is now being liquidated, remarkably five years ahead of the contractual lifetime. Investors received more than double of their commitments, yielding an IRR of 448%. The high return is attributable to the fund’s well differentiated build-and-sell strategy as well as the team’s ability to identify and exploit special situations, which enabled the fund to keep hold periods short and associated risks low.PDF Download

September 20, 2015

MerLion’s Finafloxacin Shown to be More Efficacious than Ciprofloxacin in the Treatment of Complicated Urinary Tract Infections

MerLion Pharmaceuticals (“MerLion”) today presented detailed data from its Phase 2 study in patients hospitalized with complicated urinary tract infections (cUTI) and pyelonephritis showing that a five day course of its novel antibacterial, finafloxacin, was more effective than treatment with the current standard of care (ciprofloxacin).PDF Download

September 15, 2015

MerLion to Present Detailed Phase 2 Data on Efficacy of Finafloxacin in Complicated Urinary Tract Infections at International Congress of Chemotherapy and Infection (ICC)

MerLion Pharmaceuticals (“MerLion”), a biopharmaceutical company based in Singapore and Berlin, today announced that detailed data from the Phase 2 clinical trial on the efficacy of finafloxacin will be presented at the joint Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Society of Chemotherapy (ISC) International Congress of Chemotherapy and Infection (ICC), taking place on September 17-21 in San Diego.PDF Download

September 03, 2015

Evolva announces details of rights offering

Evolva Holding SA (SIX: EVE, “Evolva” or the “Company”) today publishes the terms of the planned rights offering. As previously announced on 26 August 2015, Evolva plans to raise new equity capital to support the stevia launch and other growth initiatives. The rights offering relates to 62,412,477 new registered shares with a nominal value of CHF 0.20 each.PDF Download - English VersionPDF Download - German Version

August 21, 2015

Evolva launches nootkatone for F&F

Evolva (SIX: EVE) announces the launch of nootkatone, a highly prized citrus flavour and fragrance (F&F) ingredient. By brewing nootkatone from sugar, rather than extracting it from the skin of grapefruits, Evolva’s process allows nootkatone to be made in large amounts in a highly reproducible, contaminant free, sustainable and affordable manner. Evolva has now begun selling nootkatone as a F&F ingredient to food, beverage, personal care, and home care product producers around the world.PDF Download - English VersionPDF Download - German Version

June 11, 2015

Biotie Announces Completion of Pricing of U.S. Public Offering of ADSs and Conversion of Convertible Notes

Biotie Therapies Corp. ("Biotie" or the "Company"), a specialized drug development company focused on products for neurodegenerative and psychiatric disorders, has completed the pricing of its U.S. public offering of 3,761,418 ADSs at a price to the public of $14.888 per ADS for gross proceeds of $55,999,991.18 (€49,649,783.83 at the fixed ECB exchange rate of $1.1279 per euro as at June 10, 2015). The share to ADS ratio is 80 to one, and the ADSs will represent 300,913,440 newly issued shares in the Company with a subscription price of €0.165 (rounded figure) per new share (at the above mentioned fixed exchange rate).PDF Download

June 08, 2015

Biotie Increases Proposed U.S. Public Offering of ADSs

Biotie Therapies Corp. ("Biotie" or the "Company"), a specialized drug development company focused on products for neurodegenerative and psychiatric disorders, has decided to increase its proposed U.S. public offering from $50 million to $56 million American Depositary Shares ("ADSs") representing its shares.PDF Download

June 04, 2015

Biotie Commences Proposed U.S. Public Offering of ADSs

Biotie Therapies Oyj, a specialized drug development company focused on products for neurodegenerative and psychiatric disorders, has today commenced the marketing of a proposed U.S. public offering of $50 million American Depositary Shares ("ADSs") representing its shares, based on the authorization granted by the Annual General Meeting of shareholders on May 26, 2015.PDF Download

May 21, 2015

Chinese Consortium Enters into Agreement to Acquire Ambrx

A consortium (the “Consortium”) consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU Investments, China Everbright Limited’s healthcare fund (“CEL Healthcare Fund”), and WuXi PharmaTech announced today that the Consortium has signed a merger agreement pursuant to which the Consortium will acquire Ambrx Inc. The transaction is expected to close in the second quarter of 2015, subject to receipt of certain regulatory approvals and satisfaction of customary closing conditions. Other details of the transaction were not disclosed.PDF Download

May 20, 2015

Evolva CEO exercises options, increases his shareholding in Evolva

Evolva (SIX: EVE) today announces that Neil Goldsmith, CEO of Evolva, has exercised options that he held to acquire 3.8 million new Evolva shares, simultaneously selling 2.2 million of them to cover the acquisition costs and taxes related to the option transaction, leaving him with an additional 1.6 million shares.PDF Download - English VersionPDF Download - German Version

Evolva reaches third milestone in Roquette collaboration

May 14, 2015

¨Biotie Has Filed Registration Statement for U.S. Public Offering

In accordance with its previously announced plans, Biotie Therapies Corp. ("Biotie") has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission ("SEC") relating to its proposed U.S. public offering of American Depositary Shares, representing Biotie's ordinary shares ("ADSs"). The number of ADSs to be offered and the price range for the offering have not yet been determined. Biotie has made an initial submission to list its ADSs on the NASDAQ Global Market under the ticker symbol "BITI".PDF Download

May 11, 2015

Cargill and Evolva Start Engineering Work on Production Facility for Next-Gen Stevia Sweeteners

Evolva informs Cargill of intent to exercise 45% option

Evolva and Cargill have agreed to begin the engineering phase for converting an existing Cargill manufacturing facility to produce next-generation stevia sweeteners (steviol glycosides). The ingredients are expected to be commercially available in 2016.PDF Download - English VersionPDF Download - German Version

April 23, 2015

ARAVIS sells two German wind farms

Aravis Energy I LP, a Swiss renewable energy fund advised by Aravis, successfully completed the sale of two companies comprising two German wind farms to a Swiss power supplier. “We have once again been able to successfully exit investments, which further strengthens our track record of delivering returns to investors. This proves our agility and high-quality skills of implementing attractive investment projects in accordance with the investment strategy.’’, commented Oliver Thalmann, Managing Partner of Aravis. The German wind farms are located in Rhineland-Palatinate respectively Brandenburg. Both wind farms benefit from attractive long-term feed-in tariffs. These tariffs do not correlate with other commodity market prices such as those for oil and gas, thereby offering an efficient diversification effect to investors.PDF Download

April 23, 2015

Biotie provides update on tozadenant Phase 3 program

Biotie has further refined its plans for the design and conduct of Phase 3 trials in Parkinson's disease (PD) patients experiencing levodopa related end-of-dose 'wearing-off' (motor fluctuations). The phase 3 program will consist of a double- blind trial with an open-label extension and, providing this demonstrates safety and efficacy, will be followed by a separate open-label trial to generate further clinical safety data.PDF Download

April 23, 2015

Evolva (SIX: EVE) today announces the US government’s approval of the transfer (“novation”) of the GC-072 contract to Emergent BioSolutions Inc. (NYSE: EBS). This triggers a payment of USD 4 million to Evolva, following an initial upfront payment of USD 1.5 million in December 2014. This does not change the revenue guidance for 2015.PDF Download - English VersionPDF Download - German Version

March 26, 2015

Evolva and Valent BioSciences to co-develop agricultural bioactives

Evolva (SIX: EVE) and Valent BioSciences Corporation (VBC), a subsidiary of Tokyo-based Sumitomo Chemical Company, have signed an exclusive agreement to co-develop and commercialise a class of high-value active ingredients for use as next-generation agricultural bioactives. For competitive reasons, the ingredients are not being identified at this time.PDF Download - English VersionPDF Download - German Version

March 10, 2015

Mallinckrodt to acquire Ikaria in $2.3 bln deal. Early investor Aravis Exits along side with PE Madison Dearborn

Ikaria is being sold for $2.3 billion to global biopharmaceutical company Mallinckrodt. In 2005 Aravis, through its Biotech venture I fund, had joined the initial Series A financing of Ikaria Inc, together with 5am, Venrock and Arch. Over time through various innovative M&A and financing steps the company has grown into a highly profitable specialty company. The purchase by Mallinckrodt follows last years’ partial sale to Madison Dearborne and the listing of Ikaria’s spin out Bellorophon (BLPH; NASDAQ).PDF Download

March 10, 2015

Ajinomoto project moves into the next phase triggering a milestone payment to Evolva

Evolva (SIX: EVE) today announces that Ajinomoto Co. Inc., Japan, has confirmed that Evolva has completed the first R&D phase in their collaboration and that the collaboration is moving into its next phase. The ultimate objective of the collaboration is the joint development of novel fermentation production routes for a natural functional ingredient for application in Personal Care. Evolva has developed an innovative process that allows Ajinomoto to manufacture the target ingredient. In recognition of the progress and several new findings, Ajinomoto will make a milestone payment to Evolva.PDF Download - English VersionPDF Download - German Version

February 27, 2015

Biotie Financial Statement Release 2014

Biotie Financial Statement Release 2014 - This is a summary of the financial statement report 2014 published today.

Company Highlights October - December 2014 :

- Preparations to advance tozadenant into Phase 3 development in Parkinson's disease as part of Biotie's proprietary portfolio continued during the quarter. The Phase 3 program is expected to start recruiting patients in the middle of 2015.

- Biotie advanced SYN120, a 5-HT6 / 5-HT2a antagonist, into Phase 2 development. The SYNAPSE study, a Phase 2a clinical study in patients with Parkinson's disease dementia, started in December 2014. The study is largely funded by The Michael J. Fox Foundation (MJFF).

- Biotie's partner H. Lundbeck A/S (Lundbeck) continued the rollout of Selincro in Europe and it has now been introduced in 26 European markets. Favorable reimbursement decisions have been issued in a number of European markets, including France, Spain and the United Kingdom, where NICE issued its final positive guidance in November 2014.

- Annual impairment review of intangible assets and goodwill resulted in a non-cash impairment charge of EUR 27.6 million in respect of nepicastat and SYN120.

- Biotie's revenue in Q4 2014 was EUR 1.9 million (EUR 5.8 million) and the financial result was a net loss of EUR 32.4 million (net profit of EUR 1.7 million).

- Biotie ended 2014 with liquid assets of EUR 32.4 million (EUR 35.9 million, 30 September 2014). Operating cash flow for the full year was a net outflow of EUR 14.1 million (net inflow of EUR 10.6 million).

February 16, 2015

Aravis to present at the Innovationsforum Energie in Zurich on the 20th of March

Aravis has been invited to speak at the 5th Innovationsforum Energie in Zurich on 20th March 2015. Besides sharing practical insights from Aravis experiences in Investment in the energy sector, the following pertinent issues will be addressed:
- Analysing the market to ascertain what is the appetite of investors for European Infrastructure;
- How do Financial Investors view investments in the Energy sector today;
- What are some possible collaborations models between utilities and financial investors when financing energy infrastructure projects?

February 13, 2015

Bellerophon Therapeutics Announces Pricing of Its Initial Public Offering

Bellerophon Therapeutics announced today the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $12.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Bellerophon. In addition, Bellerophon has granted the underwriters an option to purchase up to 750,000 additional shares of common stock at the public offering price, less the underwriting discount. Bellerophon's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the ticker symbol "BLPH" on February 13, 2015. The offering is expected to close on February 19, 2015, subject to customary closing conditions.PDF Download

February 12, 2015

MerLion announces FDA approval of finafloxacin otic suspension - First novel drug from a Singapore company to achieve FDA approval

MerLion Pharmaceuticals (MerLion), a biopharmaceutical company headquartered in Singapore with clinical development operations in Berlin, Germany, today announced that an otic suspension of finafloxacin has been approved by the FDA to treat acute otitis externa, commonly known as “swimmer’s ear”, caused by Pseudomonas aeruginosa and Staphylococcus aureus. Finafloxacin was licensed by MerLion to a major North American partner in 2010 for use in North America for otic (ear) infections.PDF Download

February 09, 2015

Evolva provides financial and project update

Evolva (SIX: EVE) today provides a financial and project update.According to the provisional, unaudited financials, revenues in 2014 slightly exceeded CHF 10 million (in line with guidance), whilst the year-end cash position of CHF 60.7 million was higher than the CHF 50 million projected in November 2014.PDF Download - English VersionPDF Download - German Version

January 29, 2015

Aravis sponsors the Wind Risk Management and Mitigation Forum in London on the 4th and 5th of February

Aravis is proud to sponsor the Wind Risk Management and Mitigation Forum taking place in London on the 4th and 5th of February. The conference is organised by Wind Power Monthly, which is widely regarded as the most prestigious magazine in the wind energy sector. In addition, on the second day Aravis will be presenting the topic “Assessing The Impact Of Weather Risk On Cash Flow”. We are excited about the event and are looking forward to meeting you at the conference.